Inhibitory effect of TS-962 on the formation of early atherosclerotic lesions in high fat-fed hyperlipidemic hamsters

LDL-C-Lowering therapy: Current and future therapeutic targets

“…In experimental animal models, nonselective ACAT inhibitors have been shown to decrease plasma levels of LDL-C and to protect against atherosclerotic disease [41][42][43]. Nevertheless, human trials have been disappointing.…”

Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins

“…[25] Interestingly, T-91485 even attenueffects on the arterial wall in experimental animal models. [33][34][35] ated the myotoxicity caused by atorvastatin. Similarly, the effects However, clinical trials with ACAT inhibitors did not show beneof squalene synthase inhibition on statin-induced myotoxicity ficial changes in the lipid profile.…”

Emerging Role of Intravascular Ultrasound in the Assessment of Experimental Anti-Atherosclerotic Therapies

“…The isoform ACAT1 is widely expressed, particularly in macrophages, and therefore plays a pivotal role in the formation of foam cells, the cellular hallmark of atherosclerotic plaque [61]. Inhibition of ACAT has been reported to be beneficial in a number of animal models of atherosclerosis [62][63][64][65][66][67]. In the recently reported ACTIVATE study [68], patients with symptomatic coronary artery disease and a high rate of use of established medical therapies underwent serial IVUS analysis before and after treatment with placebo or the experimental ACAT inhibitor pactimibe.…”